

Colinz

Date : 30/07/2016

To,
Bombay Stock Exchange Limited
Phiroze Jeejeeboy Towers,
Dalal Street,
Mumbai – 400001

Dear Sir,

Sub: Outcome of the Board Meeting
BSE Code: 531210

The Meeting of Board of Directors was held on Saturday, 30th July, 2016 at 12.30 P.M. at the registered office of the Company at A-101, Pratik Industrial Estate, Next to Fortis Hospital, Mulund Link Road, Mumbai -400078 has approved the Un- audited Financial Results for the quarter ended on 30th July, 2016.

This is for your information and record.

Thanking you,

Yours faithfully,

FOR COLINZ LABORATORIES LTD



DR. L.S. MANI
MANAGING DIRECTOR
DIN: 00825886

COLINZ LABORATORIES LIMITED.

(CIN NO : L24200MH1986PLC041128)

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund Link Road, Mumbai – 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2016

(Rupees in '000')

S. No.	Particulars	Un -audited			Audited
		Quarter Ended			Year Ended
		30.06.2016	31.03.2016	30.06.2015	31.03.2016
PART - I					
1	(a) Income from Operation				
	Gross Sales	23,877	19,546	24,800	83,989
	Less: Excise Duty	1,437	1,178	686	3,036
	Net Sales	22,440	18,368	24,114	80,953
	(b) Other Operating Income	-	-	-	-
	Total Income from Operation	22,440	18,368	24,114	80,953
2	Expenditure	-	-	-	-
	(a) Consumption of Materials	2,977	6,401	4,180	17,528
	(b) Purchase of Goods Traded	2,660	4,789	1,658	13,345
	(c) (Increase)/Decrease in stock in trade	4,314	(3,636)	6,109	3,962
	(d) Staff Cost	7,376	6,622	7,290	28,623
	(e) Depreciation	663	711	702	2,818
	(f) Other Expenditure	4,006	3,155	3,482	12,985
	Total Expenditure	21,996	18,042	23,421	79,261
3	Profit /Loss from Operation Before Other Income (1-2)	444	326	693	1,692
4	Other Income /(Loss)	205	295	162	980
5	Profit /Loss before Interest & Exceptional items (3+4)	649	621	855	2,672
6	Interest	271	289	338	1,158
7	Profit /Loss after Interest but before exceptional items (5-6)	378	332	517	1,514
8	Exceptional items	-	-	-	-
9	Profit /Loss before Tax (7-8)	378	332	517	1,514
10	Tax Expenses (Provision for Taxation):				
	Current tax	(60)	80	(80)	275
	Deffered tax	-	98	(50)	293
11	Net Profit/Loss after Tax (9-10)	318	154	387	946
12	Paid up Equity Share Capital (Face Value 10/- Per Share) [Net of allotment money in arrears]	35,441	35,441	354,39	35,441
13	Reserves Excluding Revaluation Reserves	-	-	-	8,416
14	Earning per share (EPS) before extraordinary item (not Annualised) Basic & Diluted	-	-	-	0.21
PART -II	A. PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	i) Number of Shares	2,894,901	2,894,901	2,894,901	2,894,901
	ii) Percentage of shareholding	63.33%	63.33%	63.33%	63.33%
2	Promoters and promoter group Shareholding				
	a) Pledged/Encumbered				
	i) Number of shares	-	-	-	-
	ii) Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	iii) Percentage of shares (as a% of the total share capital of the company)	-	-	-	-
	b) Non-encumbered				
	i) Number of Shares	1,676,099	1,676,099	1,676,099	1,676,099
	ii) Percentage of shares (as a% of the total shareholding of promoter and promoter group)	36.67%	36.67%	36.67%	36.67%
	iii) Percentage of shares (as a % of the total share capital of the company)	100%	100%	100%	100%



B. INVESTORS COMPLAINTS Pending at Beginning of the Quarter Received During the Quarter Disposed of During the Quarter Remaining at the end of the Quarter	3 Months ended 30.06.16 NIL NIL NIL NIL
---	--


NOTES :-


1. The above results were reviewed by the Audit Committee on 29.07.2016 and approved by the Board of Directors at their meeting held on 30-07-2016
2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
3. The provision for Deffered Tax if any, will be made at the end of the Finanacial Year.
4. Previous period figures have been regrouped wherever required.

Dt:- 30.07.2016

MUMBAI.

For and on behalf of the Board
COLINZ LABORATORIES LTD.




Dr. L. S. MANI
(DIN NO : 00825886)
(Managing Director)